Sale!

Oramorph oral solution 10mg/5ml – 100ml bottle

$90.00$170.00

Oramorph oral solution 10mg/5ml is used for Mild to moderate pain, Opioid use disorder and other conditions.

Name: Oramorph

Packing: 100 mL Bottle

Clear

Description

Oramorph oral solution 10mg/5ml is used for Mild to moderate pain, Opioid use disorder and other conditions.

Oramorph oral solution 10mg/5ml is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Oramorph oral solution 10mg/5ml indications

Oramorph is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of postoperative pain.

The use of Oramorph for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed.

Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular Oramorph may be effective; however, the mode of therapy has significant limitations. Oramorph has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of Oramorph are required to produce analgesia. The higher Oramorph doses produce significant and often lifethreatening side effects. The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated IM injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection.

Continuous IV infusion of Oramorph has been employed as an alternative to traditional modes of administration. Lower doses of Oramorph produce uniform pain control because a steady Oramorph concentration is maintained. Titration of the dosage to the patient’s needs is easily achieved by adjusting the infusion rate. The lag time between the patient’s request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of IM administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous IV infusion.

In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Oramorph is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients.

For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use Oramorph to produce anesthesia.

Oramorph dosage

Initial Dosing

Oramorph oral solution 10mg/5ml should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

​Initiate the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment experience and risk factors for addiction, abuse, and misuse. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with Oramorph.

​Oramorph tablets must be taken whole. Crushing, chewing, or dissolving Oramorph tablets will result in uncontrolled delivery of Oramorph and can lead to overdose or death.

​Use of Oramorph as the First Opioid Analgesic

​Initiate treatment with Oramorph with 15 mg tablets orally every 8 or 12 hours.

​Use of Oramorph in Patients who are not Opioid Tolerant

​The starting dose for patients who are not opioid tolerant is Oramorph 15 mg orally every 12 hours. Patients who are opioid tolerant are those receiving, for one week or longer, at least 60 mg oral Oramorph per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid.

​Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.

Patients receiving other oral Oramorph formulations may be converted to Oramorph by administering one-half of the patient’s 24-hour requirement as Oramorph on an every-12-hour schedule or by administering one-third of the patient’s daily requirement as Oramorph on an every-8-hour schedule.

​Conversion from Other Opioids to Oramorph

​There are no established conversion ratios for conversion from other opioids to Oramorph defined by clinical trials. Discontinue all other around-the-clock opioid drugs when Oramorph therapy is initiated and initiate dosing using Oramorph 15 mg orally every 8 to 12 hours.

​It is safer to underestimate a patient’s 24-hour oral Oramorph requirements and provide rescue medication (e.g., immediate-release Oramorph) than to overestimate the 24-hour oral Oramorph requirements and manage an adverse reaction. While useful tables of opioid equivalents are readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and products.

Contraindictions

Oramorph is contraindicated in patients with:

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity (e.g., anaphylaxis) to Oramorph or naltrexone

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity to Oramorph or naltrexone

Oramorph Oral Solution Side-effects

The following is a list of possible side-effects that may occur from all constituting ingredients of Oramorph Oral Solution. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.

Constipation
Hormone imbalance
Reinforcement disorders
Oramorph Oral Solution may also cause side-effects not listed here. you may need other pain killers.

Additional information

Choose quantity

10 bottles, 20 bottles

Reviews

There are no reviews yet.

Be the first to review “Oramorph oral solution 10mg/5ml – 100ml bottle”

Your email address will not be published. Required fields are marked *

Select your currency
USD United States (US) dollar
EUR Euro
X